Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
1. GSK and Spero's trial for tebipenem HBr halted early due to efficacy. 2. The drug targets complicated urinary tract infections, aiding GSK's antibiotic portfolio. 3. Approval could introduce the first oral carbapenem antibiotic in the U.S. 4. The FDA plans regulatory filing for tebipenem HBr by 2025. 5. GSK's portfolio strengthens against antimicrobial resistance challenges.